We talk about what the future looks like for more personalized therapy and if sometimes no treatment is the best option.
Rodney Hicks is director of molecular imaging at the Peter MacCallum Cancer Centre and professor of medicine and radiology at the University of Melbourne. He started his career in nuclear medicine and he witnessed one of the first treatments with MIBG (Metaiodobenzylguanidine) in a patient with metastatic pheochromocytoma. For him, an eye-opener, to see the tumor shrink. He pioneered the use of PET (Positron emission tomography) and has introduced a number of novel PET tracers.
Rodney Hicks is known as a pioneer, has over 500 peer-reviewed publications and has held numerous national and international research grants.
Guest: Rodney Hicks
By: Gustav Widar and Annette Andren
Contact us: email@example.com